• About us
• Contact

Advertisement

Product › Details

antibody-drug conjugate (ADC)

	Next higher product group	cancer drug

Record changed: 2024-08-22

Advertisement

More documents for antibody-drug conjugate (ADC)

• [1] Adcendo ApS. (8/20/24). "Press Release: Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor". Copenhagen & Shanghai....
• [2] BioNTech SE. (8/19/24). "Press Release: Lift of Partial Clinical Hold for BNT326/YL202"....
• [3] Sotio Biotech a.s.. (7/16/24). "Press Release: Sotio Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline". Prague & Beijing....
• [4] Ipsen S.A.. (7/11/24). "Press Release: Ipsen and Foreseen Biotechnology Announce Exclusive Global Licensing Agreement for Antibody-Drug Conjugate with First-in-Class Potential". Paris....
• [5] BioNTech SE. (6/24/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer". Mainz & Shanghai....
• [6] Adcytherix SAS. (6/11/24). "Press Release: Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates". Marseille....
• [7] Adcendo ApS. (5/29/24). "Press Release: Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline". Copenhagen....
• [8] Pheon Therapeutics Ltd.. (5/21/24). "Press Release: Pheon Therapeutics Announces $120m Series B Financing to Fund Development of Its Differentiated ADC Pipeline". London....
• [9] ADC Therapeutics S.A.. (5/6/24). "Press Release: ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants". Lausanne....
• [10] TORL BioTherapeutics, LLC. (4/10/24). "Press Release: TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline". Los Angeles, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.